Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
NCT01433731 is registered in ClinicalTrials.gov with TetraLogic Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase 1b Study to Assess the Safety, Pharmacodynamics and Pharmacokinetics of SHP 141, A Histone Deacetylase Inhibitor, Administered Topically Up to 28 Days to Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
- Lead sponsor
- TetraLogic Pharmaceuticals
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 30, 2011
- Completion date
- September 30, 2013
- Enrollment
- 18 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.